Key Points Trulieve and Cronos are both outperforming the S&P 500. Trulieve generated $74 million in first-half free cash flow. Cronos' second-quarter revenue rose 58% year over year. 10 stocks we like better than Trulieve Cannabis › Cannabis stocks haven't exactly been the hottest corner of the market in 2026. But two names have quietly outpaced the S&P 500 . Trulieve Cannabis (NYSE: TRLV) and Cronos Group (NASDAQ: CRON) have both gained roughly 27% this year through Sept. 18. By comparison, the S&P 500 is up about 12%. And unlike many cannabis rallies we've seen over the years, these gains haven't been driven entirely by speculation. Indeed, both companies have given investors some actual numbers to work with. 1.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.